Post-line Treatment with Teniposide for C-Myc-driven Extensive-stage Small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2/MYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2/MYC and the efficacy of teniposide.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Collaborator:
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD